EMA adopts a positive opinion for a new indication for enzalutamide

On 23 October 2014, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product enzalutamide (Xtandi). Read more here.